limited success for complications of pandemic (H1N1) 2009 (5). Its broader use in treating critically ill patients has been limited, however, because ECMO requires substantial institutional and multidisciplinary commitment for implementation and is typically only available at major medical centers offering cardiovascular surgery.

Although we cannot say specifically why our patient survived, clearly, aggressive and comprehensive empiric treatment, physiologic support, and close multidisciplinary communication were vital to managing the condition of this critically ill patient. ECMO may have assisted in organ recovery and patient survival. However, further studies should be conducted to critically evaluate ECMO in the armamentarium of therapeutic options for severe pandemic (H1N1) 2009 respiratory failure.

Michael S. Firstenberg, Danielle Blais, Louis B. Louis, Kurt B. Stevenson, Benjamin Sun, and Julie E. Mangino

Author affiliation: Ohio State University Medical Center, Columbus, Ohio, USA

DOI: 10.3201/eid1512.091434

References

1. Samuels LE, Kaufman MS, Thomas MP, Holmes EC, Brockman SK, Wechsler AS. Pharmacological criteria for ventricular assist device insertion following postcardiomyotomy shock: experience with the ABIOMED BVS system. J Card Surg. 1999;14:288–93. DOI: 10.1111/j.1540-8191.1999.tb00996.x

2. Thalanany MM, Mugford M, Hibbert C, Cooper NJ, Truesdale A, Robinson S, et al. CESAR Trial Group. Methods of data collection and analysis for the economic evaluation alongside a national, multicentre trial in the UK: conventional ventilation or ECMO for severe adult respiratory failure (CESAR). BMC Health Serv Res. 2008;8:94. DOI: 10.1186/1472-6963-8-94

3. Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirsch RB. Extracorporeal life support: the University of Michigan experience. JAMA. 2000;283:904–8. DOI: 10.1001/jama.283.7.904

4. Lefrak EA, Steven PM, Pitha J, Balsinger E, Noon GP, Mayor HD. Extracorporeal membrane oxygenation for fulminary influenza pneumonia. Chest. 1974;66:385–8. DOI: 10.1378/chest.66.4.385

5. Centers for Disease Control and Prevention. Intensive-care patients with severe novel influenza A (H1N1) virus infection—Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:749–52.

Address for correspondence: Michael S. Firstenberg, Division of Cardiothoracic Surgery, Ohio State University Medical Center, 410 W 10th Ave, N817 Doan Hall, Columbus, OH 43212, USA; email: michael.firstenberg@osumc.edu

To the Editor: We report a mild to moderate respiratory disease in patients seeking treatment for influenza-like illness (ILI) within the first 8 weeks of an outbreak of influenza A (H1N1) 2009 virus (pandemic [H1N1] 2009) infection in the Province of Buenos Aires. The first cases of pandemic (H1N1) 2009 in Argentina were reported in early May 2009 in travelers returning from Mexico and the United States. In mid-June, a sharp increase was reported in the number of patients with acute respiratory symptoms who were seeking treatment in emergency rooms. By July 9th, the Argentine Ministry of Health had confirmed 2,677 cases and 82 deaths; most of those infected were residents of Buenos Aires and the surrounding area (1). Notably, some patients had clinical radiologic dissociation consistent with primary viral pneumonia. Notably, some patients had clinical radiologic dissociation characterized by cough and pulmonary infiltrates in the absence of fever. Median time of hospitalization was 36 hours (range 1–25 days). No significant differences were observed between the groups of patients that were admitted versus outpatients in terms of age, sex, number of days from initiation of fever to first hospital visit, and history of influenza vaccination. A total of 163 (98%) of 166 patients admitted to the hospital during the observation period were discharged with no further complications.
Patients admitted to the hospital with pulmonary infiltrates were empirically treated with high dose oseltamivir (150 mg 2×/d) for 5 days, other antimicrobial drugs, and, eventually, steroids. In 2 patients, the respiratory disease progressed initially but they eventually recovered; 2 patients (1.2% of admissions to hospital) with acute respiratory failure died. Despite improvement in clinical symptoms at discharge, chest radiographs performed on a limited number of patients showed no substantial changes at 72–96 h after admission.

Clinical manifestations of pandemic (H1N1) 2009 have not yet been fully characterized. We observed a mild to moderate lower respiratory disease in ≈8% of consecutive patients with ILI during the current pandemic in Argentina. A more severe respiratory disease was observed in Mexico during the current pandemic. In contrast, early reports indicated that pandemic (H1N1) 2009 disease might be similar in severity to seasonal influenza (3). A lack of microbiologic confirmation may bias our observation. Because pulmonary infiltrates are uncommon in previously healthy persons with ILI, a simultaneous circulation of other respiratory pathogens may explain our observation. Furthermore, early empirical use of antimicrobial drugs could overshadow clinical features of bacterial pneumonia.

We observed an unexpectedly high rate of lower respiratory disease in adults with ILI during an outbreak of pandemic (H1N1) 2009 in Argentina. This finding suggests that a unique pattern of virulence, pulmonary tropism, or both may characterize the current influenza A (H1N1) infection, although we could not rule out co-infection with other viral or bacterial respiratory pathogens. Considering the evolving nature of influenza viruses, the wide clinical spectrum of pandemic (H1N1) 2009 should be further investigated.

Carlos Zala and Roberto Gonzalez
Author affiliation: Hospital Central de San Isidro, Buenos Aires, Argentina
DOI: 10.3201/eid1512.091062

References
1. Alerta epidemiológico situación de influenza A H1N1 [cited 2009 Sep 29]. Available from http://municipios.msal.gov.ar/h1n1/parte_influenza/parte-62 fecha-09-07-09.pdf
2. Ministry of Health, Argentina. Notificación al Sistema Nacional de Vigilancia Laboratorial SNVS-SIVILSA: Actualización infecciones respiratorias agudas virales, todo el país hasta SE 29 incluyendo influenza A H1N1. July 29, 2009 [cited 2009 Sep 29]. Available from http://www.msal.gov.ar/htm/site/pdf/Epi-29-07.pdf
3. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiro- noes-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A H1N1 in Mexico. N Engl J Med. 2009;361:680–9. DOI: 10.1056/NEJMoa0904252
4. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605–15. DOI: 10.1056/NEJMoa0903810

Address for correspondence: Carlos Zala, Amenabar, 1750 3D, 1426 Buenos Aires, Argentina; email: czala@teletel.com.ar

Susceptibility of Poultry to Pandemic (H1N1) 2009 Virus

To the Editor: During April 2009, cases of acute respiratory disease in humans caused by influenza A pandemic (H1N1) 2009 virus in Mexico were reported (1). By August 21, 2009, a total of >182,166 human cases, including 1,799 deaths, had been reported from 177 countries (www.who.int/csr/don/2009_08_21/en/index.html).

The origin of the new virus appears to be a reassortant event of a virus from swine in North America that contained the classic swine, human, and avian influenza genes and a virus of unknown origin that contributed neuraminidase and matrix genes of swine in Europe. On May 2, 2009, the first nonhuman infections were detected in a swine operation in Canada (www.who.int/csr/don/2009_06_24/en/index.html).

Historically, human seasonal influenza A viruses have not been reported to infect poultry, but clinical cases of respiratory disease or reduction in egg production have been reported for domestic turkeys after infection with subtypes H1N1, H1N2, and H3N2 swine influenza viruses and for multiple poultry species with subtype H1N1 avian influenza virus (2–4). The presence of avian and swine influenza virus genes in pandemic (H1N1) 2009 virus increases the potential for infection in poultry after exposure to infected humans or swine.

To determine infectivity potential, 3-week-old chickens (Gallus domesticus) (n = 11), 2-week-old domestic ducks (Anas platyrhynchos) (n = 11), 73-week-old reproductively active turkey hens (Meleagris gallopavo) (n = 9), 3-week-old turkey pouls (n = 11), and 5-week-old Japanese quail (Coturnix japonica) (n = 11) were intranasally inoculated with 10^6 mean egg infectious doses of A/Mexico/4108/2009(H1N1). Five uninfectected chickens, ducks, turkey pouls, and quail, and 3 uninfected turkey hens were contact exposed to intranasally inoculated birds to assess transmission potential. Cloacal and oropharyngeal swabs were taken on 2, 4, 7, and 10 days postinoculation (DPI) from all birds, and internal tissues were taken from 2 birds on 2, 4 and 7 DPI for virus detection by quantitative real-time reverse transcription–PCR (qRT-PCR) assay.

LETTERS

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009